Asia Fresh News

Asia Fresh Stories

Archive for November 8th, 2011

Experian Moves to a New Office in Suntec, Singapore

leave a comment »

SINGAPORE, Nov. 8, 2011 /PRNewswire-Asia/ — Experian, the global information services company, recently completed its move to the new office in Suntec Singapore.

The new address is 8 Temasek Boulevard, #19-01 Suntec Tower 3, Singapore.

Located at the heart of business and finance centre, the new office of Experian Singapore offers a spacious environment, convenient transportation and other amenities which enable staff to better serve clients in and outside the office.

Mr Ken Sansom, President of Experian Asia Pacific, commented that “Singapore is the headquarters of Experian in Asia Pacific. With the rapid growth of our business and operations over the last 5 years, we decided to move our office. We have doubled our footprint to allow for further growth and reinforce our commitment to invest strongly in Singapore to support clientele across all industry verticals.”

About Experian

Experian is the leading global information services company, providing data and analytical tools to clients in more than 80 countries. The company helps businesses to manage credit risk, prevent fraud, target marketing offers and automate decision making. Experian also helps individuals to check their credit report and credit score, and protect against identity theft.

Experian plc is listed on the London Stock Exchange (EXPN) and is a constituent of the FTSE 100 index. Total revenue for the year ended 31 March 2011 was US$4.2 billion. Experian employs approximately 15,000 people in 41 countries and has its corporate headquarters in Dublin, Ireland, with operational headquarters in Nottingham, UK; California, US; and Sao Paulo, Brazil.

For more information, visit http://www.experianplc.com
For Experian Singapore, visit http://www.experian.com.sg

Experian and the marks used herein are service marks or registered trademarks of Experian Information Solutions, Inc. Other product and company names mentioned herein may be the trademarks of their respective owners.

Contact:

Margaret Lam
Experian Asia Pacific
margaret.lam@hk.experian.com

SOURCE﹛Experian

Written by asiafreshnews

November 8, 2011 at 12:11 pm

Posted in Uncategorized

Data Published in Circulation Journal Show OrbusNeich’s Genous (TM) Stent is Safe and Effective in Elderly Patients

leave a comment »

Results from the e-HEALING Registry Show No Significant Difference in Stent Thrombosis for a Patient Population with Expected Poor Compliance with Dual Antiplatelet Therapy

HONG KONG, Nov. 7, 2011 /PRNewswire-Asia/ — OrbusNeich today announced the publication of 12-month follow-up data from the e-HEALING (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth) registry in Circulation Journal( http://www.jstage.jst.go.jp/article/circj/advpub/0/1109081397/_pdf ) that show the Genous Stent is safe and effective in elderly patients.

In the study, no significant difference in stent thrombosis (ST) was observed at 12 months between elderly patients (aged 65 or older) and younger patients. The target lesion revascularization (TLR) rate was not significantly higher with increasing age. Target vessel failure (TVF), the main outcome of the study, was observed more often in elderly patients; TVF occurred in 11.7 percent of patients over the age of 75, in 8.8 percent of patients between the ages of 65 and 74, and in 7 percent of patients younger than 65. The increased rate of TVF in elderly patients was driven mainly by increased mortality.

“Early discontinuation of dual antiplatelet therapy (DAPT) has been identified as a major predictor for the occurrence of ST, and for this reason the elderly are at a particularly high-risk for ST due to their expected non-compliance with DAPT,” said Dr. Andres Iniguez of the University of Vigo, Spain. “The elderly comprise an important subgroup of patients for whom long-term DAPT may not be advisable, and these data show that in patients over 65 the Genous Stent was safe and did not lead to an increased risk of ST despite their lower compliance.”

The registry’s main outcome was TVF at 12-month follow-up, defined as the composite of cardiac death or myocardial infarction (MI) unless unequivocally attributable to a non-target vessel and target vessel revascularization (TVR). Secondary outcomes were the composite of cardiac death, MI and clinically-indicated TLR, the individual outcomes all-cause death, cardiac death, MI (non-Q-wave or Q-wave), TLR, TVR, ST, major and minor bleeding and stroke.

e-HEALING, a multi-center, worldwide prospective clinical registry conducted at 144 centers in 31 countries outside of the United States, included 4,939 patients with at least one lesion suitable for non-urgent percutaneous coronary intervention (PCI) and Genous Stent implantation. In the patient population, 2,651 were under the age of 65, 1,403 were between the ages of 65 and 74, 794 were between the ages of 75 and 84, and 75 were over the age of 85. Elderly patients were defined as patients over the age of 65 and the very elderly as patients over the age of 75.

About Genous

Genous is OrbusNeich’s patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug eluting stents and is supported by data from more than 6,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world’s first pro-healing stent, the Genous Stent, as well as other stents and balloons marketed under the names of Azule(TM), R stent, Scoreflex(TM), Sapphire(TM), Sapphire II and Sapphire NC. Development stage products include the Combo(TM) Dual Therapy Stent, the only dual therapy stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of the Genous pro-healing technology with an abluminal sirolimus drug elution. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit http://www.OrbusNeich.com.

Follow OrbusNeich on Twitter at http://www.twitter.com/OrbusNeich, and learn more about the company and the Genous technology on OrbusNeich’s YouTube Channel: http://www.youtube.com/user/OrbusNeichMedical.

SOURCE﹛OrbusNeich

Written by asiafreshnews

November 8, 2011 at 10:20 am

Posted in Uncategorized